The total market for nanobiotechnology products is $19.3 billion in 2010 and is growing at a compound annual growth rate (CAGR) of 9% to reach a forecast market size of $29.7 billion by 2015.
Medical applications, including drug delivery and microbicides, dominate today’s market, with sales of $19.1 billion in 2010. This market segment is growing at a compound annual growth rate (CAGR) of 8.7%, and is forecast to reach sales of $29 billion by 2015.
In the R&D tools market, DNA sequencing is an emerging growth opportunity for nanotechnologies. This sector is valued at $63 million in 2010 and is expected to increase at a 37% compound annual growth rate (CAGR) to reach $305 million in 2015.
STUDY GOALS AND OBJECTIVES
BCC’s goal for this study is to examine the status of current and emerging nanobiotechnologies and products and assess their worldwide growth potential over a 5-year period from 2010 to 2015. We are particularly interested in characterizing the nanobiotechnology market for drug delivery, diagnostics, R&D tools, microbicides, and DNA sequencing applications. A main focus of this report is drug delivery, where the majority of nanotechnology sales occur.
Our main objective is to present a comprehensive analysis of what constitutes the state-of-the-art for nanotech-enabled life science products and what the current and future commercial potential is for each of the key market segments.
REASONS FOR DOING THE STUDY
Nanotechnology is coming of age as a materials platform in multiple industries including the biotechnology industry. The unique properties that nanomaterials provide enable value-added performance in a range of life science applications, from encapsulating and releasing drugs to biologic imaging. At the same time, the drug industry is searching for ways to extend drugs coming off patent as well as to improve drug pharmacokinetics. The diagnostics industry is seeking ways to better image molecular events to meet demand for new medicines. Nanobiotechnology, representing a diverse range of applications and materials, is the result of these converging forces.
Several nanotechnology platforms are already established and providing significant revenues in drug delivery applications, as well as diagnostics, microbicides, and R&D tools. Significant nanotechnology drug formats include polymer, liposomal, and nanocrystal drugs. Diagnostic and microbicide formats include nanoparticles, quantum dots, and dendrimers. Nanopore formats are emerging in third-generation DNA sequencing applications.
Given the emerging nature of this industry, it is timely to analyze the key trends, markets, and industry dynamics to provide a useful basis for decision-making.
INTENDED AUDIENCE
We have compiled a study of the main nanomaterials that will be important in the five major end-user segments. We present the nanobiotechnologies and growth-driving forces, product types, key market applications, companies and alliances, future market potential, and product sales forecasts for the period 2009 through 2015. We project the future use of nano-enabled products for the key end-use segments: R&D tools, drug delivery, diagnostics, microbicides, and DNA sequencing.
We also examine the changing industry dynamics, key nanomaterials and their applications, and markets.
This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanomaterials, life sciences tools, biodefense, medical devices, polymers, DNA sequencing, and medical and biologic imaging materials.
It will also be of interest to manufacturers of quantum dots, dendrimers, nanoparticles, nanocrystals, nanopores, biochips, and polymer nanoparticles.
SCOPE OF REPORT
The study scope includes the major nanotechnology formats that are likely to become commercialized within the next 5 years. Each technology format is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2010 through 2015. Technology issues and market-driving forces are discussed.
Influencing factors, including drug delivery needs, biologic imaging trends, industry structure, and patent trends, are also discussed.
BCC examines nanobiotechnology companies and industry alliances, nanomaterial consumption by end-user industry, and market-driving forces. We profile 115 nanobiotechnology companies.
METHODOLOGY
BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug delivery, diagnostics, next-generation DNA sequencing, and microbicides.
Based on our analysis, we evaluate the potential applications of nanomaterial platforms in each of the major market segments and forecast sales revenues for 2010 through 2015.
For research tools and drug discovery and development, the study presents a forecast from 2010 through 2015 for each of the important nanomaterials and applications. For drug delivery, we forecast the market by nanomaterial and by clinical indication. For diagnostics, the report forecasts from 2010 through 2015 the demand by application, modality, and nanomaterial. For microbicides, the report forecasts from 2010 through 2015 the demand by application and nanomaterial. For DNA sequencing, the study forecasts market size by use and by sequencing generation. Finally, we forecast the overall nanobiotechnology market by geographical region.
INFORMATION SOURCES
BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tool firms, diagnostics firms, drug firms, nanomaterials firms, and leading nanotechnology research institutions. In addition, we compiled data from secondary sources including industry, trade, and government
ANALYST CREDENTIALS
John Bergin has written previous BCC Research biotechnology reports, titled Epigenomics: DNA Sequencing: Emerging Technologies and Applications; Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-Chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; Synthetic Biology: Emerging Global Markets; Biologic Imaging Reagents: Technologies and Global Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with a nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.
Global Biotechnology Industry
Chapter- 1: INTRODUCTION -- Complimentary
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE OF REPORT 2
METHODOLOGY 2
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 4
DISCLAIMER 4
Chapter-2: SUMMARY
SUMMARY 5
SUMMARY TABLE GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY END USER, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY END USER, 2009- 2015 ($ MILLIONS) 6
SUMMARY (CONTINUED) 7
Chapter-3: OVERVIEW
INTRODUCTION 8
TABLE 1 SCOPE OF THIS REPORT 8
MARKET POTENTIAL OF NANOBIOTECHNOLOGY 9
TABLE 2 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 9
NANOBIOTECHNOLOGY GROWTH DRIVING FORCES 10
TABLE 3 NANOBIOTECHNOLOGY MARKET GROWTH DRIVING FORCES 10
NANOBIOTECHNOLOGY MATERIALS PLATFORMS 11
TABLE 4 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS) 11
NANOBIOTECHNOLOGY PRODUCT LIFE CYCLE STATUS 12
TABLE 5 LIFE CYCLE STATUS OF NANOMATERIALS 12
NANOBIOTECHNOLOGY INDUSTRY 12
TABLE 6 NANOBIOTECHNOLOGY INDUSTRY 13
NANOBIOTECHNOLOGY INDUSTRY (CONTINUED) 14
Chapter-4: NANOBIOTECHNOLOGIES
NANOBIOTECHNOLOGY 15
TABLE 7 FEATURES OF NANOTECHNOLOGIES 15
HISTORY OF NANOTECHNOLOGY 15
TABLE 8 HISTORICAL TIMELINE OF NANOTECHNOLOGY, 1931- 2007 16
NANOTECHNOLOGY VALUE CHAIN 17
TABLE 9 VALUE CHAIN FOR NANOTECHNOLOGIES 18
BIO-NANOMATERIALS 18
OVERVIEW 18
TABLE 10 NANOBIOTECHNOLOGY MATERIALS 18
APPLICATIONS STATUS 19
TABLE 11 NANOMATERIALS APPLICATIONS STATUS 19
LIFE CYCLE STATUS 20
TABLE 12 NANOMATERIALS LIFE CYCLE STATUS 21
NANOPARTICLES 21
NANOPARTICLES (CONTINUED) 22
TABLE 13 NANOPARTICLES IN IMAGING APPLICATIONS 23
QUANTUM DOTS 24
TABLE 14 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS 25
FIGURE 1 QUANTUM DOT SPECTRA 25
FIGURE 2 FLUORESCENT DYE SPECTRA 26
LIPOSOMES 27
TABLE 15 LIPOSOME TYPES 28
DENDRIMERS 28
NANOPORES 29
TECHNICAL FEASIBILITY OF NANOPORE SEQUENCING 30
NANOCRYSTALS 31
TABLE 16 ADVANTAGES OF NANOCRYSTAL DRUG TECHNOLOGY 32
POLYMER STRUCTURES 33
INTEGRATED NANOSTRUCTURES 33
INTEGRATED NANOSTRUCTURES (CONTINUED) 34
INTEGRATED NANOSTRUCTURES (CONTINUED) 35
Chapter-5: NANOBIOTECHNOLOGY APPLICATIONS
INTRODUCTION 36
TABLE 17 NANOBIOTECHNOLOGY MATERIALS/APPLICATIONS MATRIX 36
DRUG DELIVERY APPLICATIONS 37
TABLE 18 BENEFITS OF IMPROVED DRUG DELIVERY 37
TABLE 19 KEY NANOMATERIALS IN DRUG DELIVERY 38
TABLE 20 NUMBER OF COMMERCIAL DRUGS USING NANOTECHNOLOGY, BY INDICATION, SEPTEMBER 2010 38
TABLE 21 MARKETED NANO-BASED DRUGS, 2010 39
TABLE 21 (CONTINUED) 40
TABLE 22 STATUS OF AMPHOTERICIN B 41
TARGETED DELIVERY 42
TABLE 23 TARGETED VERSUS NONTARGETED DRUG DELIVERY 43
SIRNA DRUG DELIVERY 43
FIGURE 3 RNAI SYSTEMIC DELIVERY APPROACHES 44
BIOLOGIC IMAGING APPLICATIONS 45
TABLE 24 KEY BIOLOGIC IMAGING NANO-REAGENT TYPES 46
WHY NANOPARTICLES ARE IMPORTANT FOR IMAGING 47
SUMMARY OF NANOPARTICLE IMAGING APPLICATIONS 48
TABLE 25 NANOPARTICLES IN IMAGING APPLICATIONS 49
In Vivo Imaging 49
TABLE 26 NANOPARTICLE IN VIVO DIAGNOSTICS PIPELINE 50
TABLE 26 (CONTINUED) 51
In Vitro Imaging 52
TABLE 27 NANOSPHERE IN VITRO DIAGNOSTICS REAGENTS PIPELINE 52
Genomics, Proteomics and Cell Biology Imaging 53
EMERGING APPLICATIONS OF IMAGING REAGENTS 53
FIGURE 4 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 54
ADVANCED IMAGING NANO-REAGENTS 55
TABLE 28 EMERGING BIOLOGIC NANO-IMAGING REAGENT FUNCTIONS 55
Dual Modality Reagents 55
Multifunctional Reagents 56
Multiplexed Reagents 57
SEQUENCING APPLICATIONS 57
TABLE 29 SEQUENCING KEY NANOMATERIALS 58
TABLE 30 USE OF NANOMATERIALS, BY SEQUENCING PLATFORM 58
SEQUENCING APPLICATIONS (CONTINUED) 59
FIGURE 5 $1,000 GENOME PROGRAM AWARDS, BY TECHNOLOGY, 2007-2009 60
RESEARCH TOOLS APPLICATIONS 61
MICROBICIDE APPLICATIONS 61
TABLE 31 APPLICATIONS OF NANOMATERIALS IN MICROBICIDES 62
Chapter-6: NANOBIOTECHNOLOGY INDUSTRY STRUCTURE
INDUSTRY OVERVIEW 63
TABLE 32 NANOBIOTECHNOLOGY MATERIALS/APPLICATIONS MATRIX 63
DRUG DELIVERY INDUSTRY 64
TABLE 33 DRUG DELIVERY INDUSTRY POSITION, BY NANOMATERIAL 65
TABLE 34 DRUG DELIVERY COMPETITOR POSITION 66
TABLE 34 (CONTINUED) 67
TABLE 34 (CONTINUED) 68
TABLE 34 (CONTINUED) 69
TABLE 35 COMPANIES SPECIALIZING IN DRUG DELIVERY OF BIOMOLECULES 69
NANOPORE SEQUENCING INDUSTRY 70
TABLE 36 SEQUENCING INSTRUMENT COMPETITORS, BY TECHNOLOGY 70
TABLE 36 (CONTINUED) 71
QUANTUM DOTS INDUSTRY 72
TABLE 37 QUANTUM DOTS KEY COMPETITORS 72
ACQUISITIONS AND STRATEGIC ALLIANCES 73
TABLE 38 NANOBIOTECHNOLOGY INDUSTRY ACQUISITIONS, 2007-2010 74
TABLE 39 NANOBIOTECHNOLOGY INDUSTRY STRATEGIC ALLIANCES, 2007-2010 75
TABLE 39 (CONTINUED) 76
ACQUISITIONS AND STRATEGIC … (CONTINUED) 77
ACQUISITIONS AND STRATEGIC … (CONTINUED) 78
Chapter-7: NANOBIOTECHNOLOGY MARKETS
MARKET GROWTH DRIVING FORCES 79
TABLE 40 NANOBIOTECHNOLOGY MARKET GROWTH DRIVING FORCES 79
TABLE 41 NANOBIOTECHNOLOGY PEER-REVIEWED PUBLICATIONS, 1990-2009 80
NANOBIOTECHNOLOGY MARKET SUMMARY 81
NANOPRODUCTS MARKETS BY PLATFORM 81
TABLE 42 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS) 81
NANOPRODUCTS MARKETS BY APPLICATION 82
TABLE 43 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 83
TABLE 44 GLOBAL VALUE OF RESEARCH TOOLS MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 83
TABLE 45 GLOBAL VALUE OF RESEARCH TOOLS MARKET, BY NANOPLATFORM, THROUGH 2015 ($ MILLIONS) 84
DNA SEQUENCING MARKET 85
TABLE 46 GLOBAL VALUE OF NANOBIOTECHNOLOGY SEQUENCING MARKET, THROUGH 2015 ($ MILLIONS) 85
TABLE 47 GLOBAL VALUE OF SANGER AND NEXT-GENERATION NANO-ENABLED SAMPLE PREPARATION MARKET, BY SEQUENCING GENERATION, THROUGH 2015 ($ MILLIONS) 86
TABLE 48 GLOBAL VALUE OF THE NANO-ENABLED NANOPORE SEQUENCING MARKET, BY PRODUCT TYPE, THROUGH 2015 ($ MILLIONS) 86
TABLE 49 GLOBAL VALUE OF THE NANO-ENABLED SEQUENCING MARKET, BY NANOPLATFORM, THROUGH 2015 ($ MILLIONS) 87
DIAGNOSTICS MARKET 88
DIAGNOSTICS MARKET SUMMARY 88
TABLE 50 GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 88
TABLE 51 GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY MODALITY, THROUGH 2015 ($ MILLIONS) 89
Diagnostics Market Summary (Continued) 90
TABLE 52 GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 91
MRI MARKET 91
TABLE 53 GLOBAL VALUE OF THE NANO-ENABLED MRI DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 92
IN VITRO DIAGNOSTICS MARKETS 93
TABLE 54 GLOBAL VALUE OF THE NANO-ENABLED IN VITRO DIAGNOSTICS MARKET, BY ASSAY TYPE, THROUGH 2015 ($ MILLIONS) 93
TABLE 55 GLOBAL VALUE OF THE NANO-ENABLED IN VITRO DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 94
IN VITRO DIAGNOSTICS NANOPARTICLES MARKETS 95
TABLE 56 GLOBAL VALUE OF NANOPARTICLE IN VITRO DIAGNOSTICS, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS) 95
TABLE 57 GLOBAL VALUE OF GOLD NANOPARTICLE IN VITRO DIAGNOSTICS, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 96
MICROBICIDES MARKET 96
TABLE 58 GLOBAL VALUE OF THE NANO-ENABLED MICROBICIDES MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS) 96
FIGURE 6 BRANDED CONDOM MANUFACTURER WORLDWIDE MARKET SHARES, 2010 (%) 97
FIGURE 6 (CONTINUED) 98
TABLE 59 GLOBAL VALUE OF NANO-ENABLED MICROBICIDES MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS) 98
DRUG DELIVERY MARKET 99
TABLE 60 GLOBAL VALUE OF DRUG DELIVERY NANOPRODUCTS MARKET, BY INDICATION, THROUGH 2015 ($ MILLIONS) 100
TABLE 61 GLOBAL VALUE OF THE NANO-ENABLED DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 101
TABLE 62 GLOBAL VALUE OF THE NANO-ENABLED CANCER DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 102
TABLE 63 GLOBAL VALUE OF NANO-ENABLED CNS DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 103
TABLE 64 GLOBAL VALUE OF NANO-ENABLED ANTI-INFECTIVE DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 104
TABLE 65 GLOBAL VALUE OF NANO-ENABLED LIPID DISORDER DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 105
TABLE 66 GLOBAL VALUE OF NANO-ENABLED “OTHER” DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS) 106
NANOBIOTECHNOLOGY MARKETS BY GEOGRAPHY 106
TABLE 67 GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 107
Chapter-8: NANOBIOTECHNOLOGY PATENT STATUS
NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY 108
FIGURE 7 NUMBER OF NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 108
FIGURE 7 (CONTINUED) 109
DRUG DELIVERY PATENTS 109
FIGURE 8 NUMBER OF DRUG DELIVERY NANOBIOTECHNOLOGY PATENTS BY NANOMATERIAL PLATFORM, 2000 TO SEPTEMBER 2010 110
FIGURE 9 NUMBER OF DRUG DELIVERY NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 (%) 111
FIGURE 10 NUMBER OF LIPOSOMAL DRUG DELIVERY PATENTS BY GEOGRAPHY, 2000 TO 2010 112
FIGURE 10 (CONTINUED) 113
FIGURE 11 NUMBER OF NANOPARTICLE DRUG DELIVERY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 113
FIGURE 11 (CONTINUED) 114
Chapter-9: COMPANY PROFILES
ABBOTT GMBH & CO. KG 115
ABRAXIS BIOSCIENCE 115
ACCESS PHARMACEUTICALS, INC. 116
ACUSPHERE, INC. 117
TABLE 68 ACUSPHERE PRODUCT PIPELINE 117
TABLE 69 ACUSPHERE PATENT ESTATE 118
ACRYMED, INC. 118
AION DIAGNOSTICS 119
ALNIS BIOSCIENCES INC. 120
AMAG PHARMACEUTICALS, INC. 120
TABLE 70 AMAG MOLECULAR IMAGING REAGENTS PIPELINE 121
TABLE 71 AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES 122
AGILENT TECHNOLOGIES, INC. 122
AGILENT TECHNOLOGIES, INC.(CONTINUED) 123
ALLERGAN, INC. 124
ALLTRACEL PHARMACEUTICALS, PLC 124
ALPHA RX, INC. 125
ANSON NANO-BIOTECHNOLOGY CO. LTD. 125
APHIOS CORPORATION 125
AQUANOVA AG 126
ARMAGEN TECHNOLOGIES, INC. 126
ARTIFICIAL CELL TECHNOLOGIES, INC. 126
AZAYA THERAPEUTICS 127
BASE4 INNOVATION LTD. 127
BAXTER INTERNATIONAL INC. 128
BBI INTERNATIONAL 128
BILCARE LIMITED 129
BIND BIOSCIENCES, INC. 129
BIOALLIANCE PHARMA 130
BIOCON 131
BIODELIVERY SCIENCES INTERNATIONAL, INC. 131
BIO-GATE AG 132
BIONANOMATRIX, INC. 132
BIOPHAN TECHNOLOGIES, INC. 133
BIOSANTÉ PHARMACEUTICALS INC. 133
BIO-SYNECTICS, INC. 134
CALANDO PHARMACEUTICAL 134
CAMURUS AB 135
CAPSULUTION PHARMA AG 136
CELSION CORPORATION 136
TABLE 72 CELSION LIPOSOMAL PLATFORM STATUS 137
CENTOCOR ORTHO BIOTECH INC. 137
CERAMISPHERE PTY LTD 138
CERULEAN PHARMA INC. 138
CHEMICELL GMBH 139
CRITITECH, INC. 139
CSL BEHRING 140
CYTIMMUNE SCIENCES, INC. 140
DAMAGE PREVENTION CONCEPT 140
DENDRITECH, INC. 141
ELAN CORPORATION PLC 141
ELECTRONIC BIO SCIENCES 142
ENDOCYTE 143
ENZON PHARMACEUTICALS 143
EPITARGET AS 144
EVIDENT TECHNOLOGIES 144
EXILICA LIMITED 145
FERROPHARM GMBH 145
FLAMEL TECHNOLOGIES 146
FRESNIUS KABI AG 146
GE HEALTHCARE UK LTD. 147
GILEAD SCIENCES, INC. 147
GRACEWAY PHARMACEUTICALS, LLC 148
HANA BIOSCIENCES, INC. 148
HUMAN GENOME SCIENCES 148
IMMUNOVACCINE 149
INDIANA NANOTECH LLC 149
INTERNATIONAL BUSINESS MACHINES CORP. 150
JOHNSON & JOHNSON, INC. 150
KEREOS, INC. 151
TABLE 73 KEREOS IMAGING REAGENTS PIPELINE 152
TABLE 74 KEREOS STRATEGIC ALLIANCES 153
LABOPHARM INC. 153
LIFECARE INNOVATIONS PVT. LTD. 154
LIPLASOME PHARMA APS 154
LIPOXEN 155
LUNA NANOWORKS 156
MARINA BIOTECH 157
MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD. 157
MYMETICS S.A. 158
NABSYS, INC. 158
NANOBIO CHEMICALS INDIA PRIVATE LIMITED 159
NANOBIOTIX 159
NANOBIOSYM, INC. 160
NANOCARRIER CO., LTD. 160
NANOCO TECHNOLOGIES LTD. 161
NANOCOPOEIA, INC. 162
NANOCYTE INC. 162
NANOPROBES, INC. 163
NANOSPECTRA BIOSCIENCES, INC. 164
NANOSPHERE, INC. 164
NANOTOX 165
NANOVECTOR, INC. 165
NATCO PHARMA LIMITED 165
NOVAVAX, INC. 166
NOVOSOM AG 166
NOVOZYMES BIOPHARMA US INC. 166
OCTOPLUS N.V. 167
OXFORD NANOPORE TECHNOLOGIES LTD. 167
OXFORD NANOPORE TECHNOLOGIES LTD. (CONTINUED) 168
OXONICA INC. 169
PACIRA PHARMACEUTICALS 169
PANACEA BIOTEC LTD. 170
PCI BIOTECH AS 170
SALVONA TECHNOLOGIES INC. 171
SCHERING-PLOUGH 171
SELAH TECHNOLOGIES, LLC 172
SELECTA BIOSCIENCES 172
SEQUENOM, INC. 173
SEQUENOM, INC. (CONTINUED) 173
SEQUENOM, INC. (CONTINUED) 174
SEQUENOM, INC. (CONTINUED) 175
SIEMENS AG 176
SIGMA-TAU PHARMACEUTICALS, INC. 176
SKYEPHARMA PLC 177
SMITH & NEPHEW PLC 178
SNOGG AS 178
SOPHERION THERAPEUTICS, LLC 178
STARPHARMA HOLDINGS LTD 179
TABLE 75 STARPHARMA STRATEGIC ALLIANCES 180
SUPRATEK PHARMA 181
TEKMIRA PHARMACEUTICALS 181
TEVA PHARMACEUTICALS 181
UNIDYM, INC. 182
VIVE NANO INC. 182
